VIDEO: Latest Healio Rheumatology covers biosimilar switching and the nocebo effect
Click Here to Manage Email Alerts
Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, offered a breakdown of the July issue, including the cover story delving into the issue of interchangeable biosimilar switching.
“First, biosimilars,” Calabrese said. “We have some key opinion leaders who talk about the business, the clinical and the operational side of biosimilars.”
The cover story features contributions from a host of experts, including John R.P. Tesser, MD; Madelaine A. Feldman, MD, FACR; Allan Gibofsky, MD, JD; and Robert W. Levin, MD. For his own part, Calabrese’s editorial discusses the placebo and nocebo effect as it relates to biosimilar switching.
In addition to the cover and editorial, the issue includes meeting news coverage about opioid use in patients with rheumatic diseases. Finally, Alfred Kim, MD, PhD, provides an update on the state of COVID-19 vaccinations for immunocompromised patients.
“Al Kim — one of my favorite guys — really giving us the bottom line of what’s going with vaccines and COVID as we move ahead,” Calabrese said. “We’re on a good glide-path for now, but that’s no guarantee of future returns, as they say.”
Calabrese invites readers to dig in to the July issue of Healio Rheumatology by clicking here.
Collapse
Healio interview
Read more about
Click Here to Manage Email Alerts